Loading...
Please wait, while we are loading the content...
Similar Documents
Vancomycin Ophthalmic Ointment 1% for methicillin-resistant Staphylococcus aureus or methicillin-resistant Staphylococcus epidermidis infections: a case series.
| Content Provider | Europe PMC |
|---|---|
| Author | Sotozono, Chie Fukuda, Masahiko Ohishi, Masao Yano, Keiko Origasa, Hideki Saiki, Yoshinori Shimomura, Yoshikazu Kinoshita, Shigeru |
| Copyright Year | 2013 |
| Abstract | ObjectivesTo investigate the efficacy and safety of Vancomycin Ophthalmic Ointment 1% (Toa Pharmaceutical Co., Ltd, Toyama, Japan) in patients with external ocular infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE).DesignA case series.SettingThis study was a multicentre, open-label, uncontrolled study in Japan approved as orphan drug status.ParticipantsPatients with MRSA or MRSE external ocular infections unresponsive to the treatment of fluoroquinolone eye drops.InterventionsVancomycin Ophthalmic Ointment 1% was administered four times daily.Primary and secondary outcome measuresThe subjective and objective clinical scores and bacterial cultures were collected at days 0 (baseline), 3, 7 and 14. The primary outcome was clinical response evaluation (efficacy rate) determined as complete response, partial response, no response and worsening. Secondary outcome was the eradication of the bacteria. Safety was assessed by adverse events including cases in which neither MRSA nor MRSE was detected.ResultsTwenty-five cases with MRSA (20) or MRSE (5) infections were enrolled. Of these 25 cases, 4 discontinued the treatment due to the negative results for bacterial culture during screening or at baseline. Of the 21 cases with conjunctivitis (14), blepharitis (3), meibomitis (1), dacryocystitis (2) or keratitis (1), 14 (66.7%) cases were evaluated as being excellently (complete response, 2 cases) or well (partial response, 12 cases) treated. The eradication rates were 68.4% in MRSA (13 of 19 cases) and 100% in MRSE (2 of 2 cases). Ten adverse events occurred in 7 (28.0%) of 25 cases at the local administration site.ConclusionsVancomycin Ophthalmic Ointment 1% was considered to be useful for the treatment of intractable ocular MRSA/MRSE infections. |
| Journal | BMJ Open |
| Volume Number | 3 |
| PubMed Central reference number | PMC3563129 |
| Issue Number | 1 |
| PubMed reference number | 23364319 |
| e-ISSN | 20446055 |
| DOI | 10.1136/bmjopen-2012-001206 |
| Language | English |
| Publisher | BMJ Publishing Group |
| Publisher Date | 2013-01-29 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
| Subject Keyword | Infections |
| Content Type | Text |
| Resource Type | Article |
| Subject | Medicine |
